Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cancer Therapy Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Direct Oral Anticoagulants and Cancer-related Venous Thromboembolism: Insights from an Updated Meta-Analysis

Abstract

Introduction

Cancer-associated venous thromboembolism (VTE) presents a complex clinical challenge, with the need to balance effective anticoagulation against the risk of bleeding. Direct oral anticoagulants (DOACs) offer convenience but their efficacy and safety in this context remain debated. This systematic review and meta-analysis endeavor to evaluate the effectiveness and safety of DOACs in managing VTE associated with cancer. The findings offer essential perspectives to guide clinical decision-making.

Methods

We performed an exhaustive search across electronic databases such, as PubMed, EMBASE, and the Cochrane CENTRAL, spanning from their inception to December 15, 2023. Only English-published articles evaluating the effectiveness and safety of DOACs in managing cancer-associated VTE were considered. Evaluation criteria encompassed recurrent VTE, major bleeding (MB), clinically significant non-major bleeding (CSNMB), and clinically relevant bleeding (CRB). Statistical analyses were conducted utilizing Comprehensive Meta-Analysis software.

Results

From the 1195 records, 8 studies with 3913 patients were included. DOACs demonstrated a significant reduction in recurrent VTE risk (OR: 0.73, CI 95%: 0.57-0.93, =0.01) compared to traditional anticoagulants. However, there was a marginal increase in MB risk (OR: 1.24, CI 95%: 0.90-1.69, =0.17) with DOACs, though not statistically significant. Notably, DOACs were associated with a higher risk of CRNMB (OR: 1.64, CI 95%: 1.24-2.17, <0.001) and CRB (OR: 1.22, CI 95%: 1.00-1.52, =0.04). No publication bias was observed. Gastrointestinal cancer, Rivaroxaban/apixaban use, switching from dalteparin, improved physical function with DOACs, specific tumor sites, and older age subgroups were predictors for bleeding complications in cancer patients on anticoagulant therapy.

Conclusion

This meta-analysis provides evidence supporting the efficacy of DOACs in reducing VTE recurrence in cancer patients. However, the increased risk of bleeding complications warrants careful consideration in personalized treatment decisions. Ongoing research is necessary to refine therapeutic strategies in this complex clinical landscape.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947322285241004075557
2024-10-16
2024-11-26

  • From This Site

    /content/journals/cctr/10.2174/0115733947322285241004075557
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Khorana A.A. Mackman N. Falanga A. Pabinger I. Noble S. Ageno W. Moik F. Lee A.Y.Y. Cancer-associated venous thromboembolism. Nat. Rev. Dis. Primers 2022 8 1 11 10.1038/s41572‑022‑00336‑y 35177631
    [Google Scholar]
  2. Timp J.F. Braekkan S.K. Versteeg H.H. Cannegieter S.C. Epidemiology of cancer-associated venous thrombosis. Blood 2013 122 10 1712 1723 10.1182/blood‑2013‑04‑460121 23908465
    [Google Scholar]
  3. Khorana A.A. Carrier M. Garcia D.A. Lee A.Y.Y. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J. Thromb. Thrombolysis 2016 41 1 81 91 10.1007/s11239‑015‑1313‑4 26780740
    [Google Scholar]
  4. Streiff M.B. Holmstrom B. Angelini D. Ashrani A. Bockenstedt P.L. Chesney C. Fanikos J. Fenninger R.B. Fogerty A.E. Gao S. Goldhaber S.Z. Gundabolu K. Hendrie P. Lee A.I. Lee J.T. Mann J. McMahon B. Millenson M.M. Morton C. Ortel T.L. Ozair S. Paschal R. Shattil S. Siddiqi T. Smock K.J. Soff G. Wang T.F. Williams E. Zakarija A. Hammond L. Dwyer M.A. Engh A.M. NCCN guidelines insights: Cancer-associated venous thromboembolic disease, version 2.2018. J. Natl. Compr. Canc. Netw. 2018 16 11 1289 1303 10.6004/jnccn.2018.0084 30442731
    [Google Scholar]
  5. Chai-Adisaksopha C. Iorio A. Crowther M.A. de Miguel J. Salgado E. Zdraveska M. Fernández-Capitán C. Nieto J.A. Barillari G. Bertoletti L. Monreal M. Aibar M.A. Arcelus J.I. Ballaz A. Barba R. Barrón M. Barrón-Andrés B. Bascuñana J. Blanco-Molina A. Bueso T. Calvo B. Cañada G. Cañas I. Casado I. Culla A. de Miguel J. del Toro J. Díaz-Peromingo J.A. Falgá C. Fernández-Capitán C. Font C. Font L. Gallego P. García-Bragado F. Gómez V. González J. Grau E. Guil M. Guirado L. Gutiérrez J. Hernández G. Hernández-Blasco L. Isern V. Jara-Palomares L. Jaras M.J. Jiménez D. Lacruz B. Lecumberri R. Lobo J.L. López-Jiménez L. López-Reyes R. López-Sáez J.B. Lorente M.A. Lorenzo A. Madridano O. Maestre A. Manrique-Abos I. Marchena P.J. Martín-Antorán J.M. Martín-Martos F. Monreal M. Morales M.V. Morillo R. Nauffal D. Nieto J.A. Nieto S. Núñez M.J. Odriozola M. Otalora S. Otero R. Pagán B. Pedrajas J.M. Pérez C. Peris M.L. Pons I. Porras J.A. Ramirez L. Riera A. Rivas A. Rodríguez C. Rodríguez-Dávila M.A. Rosa V. Ruiz-Giménez N. Sampériz A. Sánchez R. Sala M.C. Sahuquillo J.C. Sanz O. Soler S. Suárez-González I. Suriñach J.M. Tiberio G. Tolosa C. Trujillo-Santos J. Uresandi F. Valero B. Valle R. Vela J. Vicente M.P. Vidal G. Vilella-Tomás V. Villalta J. Malfante P.C. Vanassche T. Verhamme P. Wells P. Hirmerova J. Malý R. Tomko T. Celis G. Salgado E. Sánchez G.T. Bertoletti L. Bura-Riviere A. Farge-Bancel D. Hij A. Mahé I. Merah A. Quere I. Papadakis M. Braester A. Brenner B. Tzoran I. Apollonio A. Barillari G. Bertone A. Bilora F. Bucherini E. Candelero G. Ciammaichella M. Di Micco P. Ferrazzi P. Grandone E. Lessiani G. Lodigiani C. Mastroiacovo D. Pace F. Pesavento R. Pinelli M. Prandoni P. Rosa M. Rota L. Tiraferri E. Tonello D. Tufano A. Venturelli U. Visonà A. Zalunardo B. Drucka E. Kigitovica D. Skride A. Sousa M.S. Bosevski M. Zdraveska M. Bounameaux H. Mazzolai L. Serrano J.C. Vitamin K antagonists after 6 months of low-molecular-weight heparin in cancer patients with venous thromboembolism. Am. J. Med. 2018 131 4 430 437 10.1016/j.amjmed.2017.11.042 29274307
    [Google Scholar]
  6. Falanga A. Zacharski L. Deep vein thrombosis in cancer: The scale of the problem and approaches to management. Ann. Oncol. 2005 16 5 696 701 10.1093/annonc/mdi165 15802275
    [Google Scholar]
  7. Bianconi A. Prior A. Zona G. Fiaschi P. Anticoagulant therapy in high grade gliomas: A systematic review on state of the art and future perspectives. J. Neurosurg. Sci. 2023 67 2 236 240 10.23736/S0390‑5616.21.05536‑3 34763392
    [Google Scholar]
  8. Masini M. Toma M. Spallarossa P. Porto I. Ameri P. Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism. Curr. Oncol. Rep. 2023 25 9 979 987 10.1007/s11912‑023‑01428‑y 37278934
    [Google Scholar]
  9. Ay C. Beyer-Westendorf J. Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann. Oncol. 2019 30 6 897 907 10.1093/annonc/mdz111 30918939
    [Google Scholar]
  10. O’Connell C. Escalante C.P. Goldhaber S.Z. McBane R. Connors J.M. Raskob G.E. Treatment of cancer‐associated venous thromboembolism with low‐molecular‐weight heparin or direct oral anticoagulants: Patient selection, controversies, and caveats. Oncologist 2021 26 1 e8 e16 10.1002/onco.13584 33275319
    [Google Scholar]
  11. Douros A. Filliter C. Azoulay L. Tagalakis V. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. Thromb. Res. 2021 202 128 133 10.1016/j.thromres.2021.03.026 33836492
    [Google Scholar]
  12. Ogino Y. Ishigami T. Minamimoto Y. Kimura Y. Akiyama E. Okada K. Matsuzawa Y. Maejima N. Iwahashi N. Hibi K. Kosuge M. Ebina T. Ishikawa T. Tamura K. Kimura K. Direct oral anticoagulant therapy for cancer-associated venous thromboembolism in routine clinical practice. Circ. J. 2020 84 8 1330 1338 10.1253/circj.CJ‑20‑0084 32624519
    [Google Scholar]
  13. Moher D. Shamseer L. Clarke M. Ghersi D. Liberati A. Petticrew M. Shekelle P. Stewart L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015 4 1 1 9 10.1186/2046‑4053‑4‑1 25554246
    [Google Scholar]
  14. Raskob G.E. van Es N. Verhamme P. Carrier M. Di Nisio M. Garcia D. Grosso M.A. Kakkar A.K. Kovacs M.J. Mercuri M.F. Meyer G. Segers A. Shi M. Wang T.F. Yeo E. Zhang G. Zwicker J.I. Weitz J.I. Büller H.R. Edoxaban for the treatment of cancer-associated venous thromboembolism. N. Engl. J. Med. 2018 378 7 615 624 10.1056/NEJMoa1711948 29231094
    [Google Scholar]
  15. Young A.M. Marshall A. Thirlwall J. Chapman O. Lokare A. Hill C. Hale D. Dunn J.A. Lyman G.H. Hutchinson C. MacCallum P. Kakkar A. Hobbs F.D.R. Petrou S. Dale J. Poole C.J. Maraveyas A. Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in cancer patients with venous thromboembolism: Results of a randomized trial (SELECT-D). J. Clin. Oncol. 2018 36 20 2017 2023 10.1200/JCO.2018.78.8034 29746227
    [Google Scholar]
  16. Agnelli G. Becattini C. Meyer G. Muñoz A. Huisman M.V. Connors J.M. Cohen A. Bauersachs R. Brenner B. Torbicki A. Sueiro M.R. Lambert C. Gussoni G. Campanini M. Fontanella A. Vescovo G. Verso M. Apixaban for the treatment of venous thromboembolism associated with cancer. N. Engl. J. Med. 2020 382 17 1599 1607 10.1056/NEJMoa1915103 32223112
    [Google Scholar]
  17. McBane R.D. II Wysokinski W.E. Le-Rademacher J.G. Zemla T. Ashrani A. Tafur A. Perepu U. Anderson D. Gundabolu K. Kuzma C. Perez Botero J. Leon Ferre R.A. Henkin S. Lenz C.J. Houghton D.E. Vishnu P. Loprinzi C.L. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial. J. Thromb. Haemost. 2020 18 2 411 421 10.1111/jth.14662 31630479
    [Google Scholar]
  18. Mokadem M.E. Hassan A. Algaby A.Z. Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular 2021 29 5 745 750 10.1177/1708538120971148 33153401
    [Google Scholar]
  19. Kim J.H. Yoo C. Seo S. Jeong J.H. Ryoo B.Y. Kim K. Lee J.B. Lee K.W. Kim J.W. Kim I.H. Kang M. Ryu H. Cheon J. Park S.R. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers (Basel) 2022 14 3 559 10.3390/cancers14030559 35158827
    [Google Scholar]
  20. Planquette B. Bertoletti L. Charles-Nelson A. Laporte S. Grange C. Mahé I. Pernod G. Elias A. Couturaud F. Falvo N. Sevestre M.A. Ray V. Burnod A. Brebion N. Roy P.M. Timar-David M. Aquilanti S. Constans J. Bura-Rivière A. Brisot D. Chatellier G. Sanchez O. Meyer G. Girard P. Mismetti P. Meyer G. Mismetti P. Chatellier G. Laporte S. Decousus H. Mahé I. Falvo N. Delluc A. Bertoletti L. Laneau C. Dinut A. Aegerter P. Emmerich J. Decousus H. Girard P. Messas E. Revel M-P. Charles-Nelson A. Laporte S. Bertoletti L. Acassat S. Mismetti P. Grange C. Meyer G. Planquette B. Sanchez O. Mahé I. Plaisance L. Poénou G. Pernod G. Imbert B. Zenati N. Couturaud F. Le Moigne E. Le Mao R. Hoffmann C. Elias A. Elias M. Falvo N. Loffroy R. Jandot M. Sevestre M-A. Modéliar Rémond S.S. Ray V. Burnod A. Roy P-M. Moumneh T. Henni S. Brebion N. Timor-David M. Constans J. Boulon C. Aquilanti S. Brisot D. Bura-Rivière A. Bertoletti L. Couturaud F. Girard P. Laporte S. Mahé I. Meyer G. Mismetti P. Planquette B. Sanchez O. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: A randomized trial. Chest 2022 161 3 781 790 10.1016/j.chest.2021.09.037 34627853
    [Google Scholar]
  21. Schrag D. Uno H. Rosovsky R. Rutherford C. Sanfilippo K. Villano J.L. Drescher M. Jayaram N. Holmes C. Feldman L. Zattra O. Farrar-Muir H. Cronin C. Basch E. Weiss A. Connors J.M. Sumida K.N.M. Martin R.C. Grosse Perdekamp M.T. Yan B. Doll D. Abraham A.N.J. Wang T-F. Jones R.M. Sivapiragasm A. Levine E.G. Haider K. Rosenblatt P.M. Fleshman J.W. Irvin W.J. Jr Raghavendra M. Dean A.R. Goodman M.M. Hong S. Baumann Kreuziger L.M. Bowman I.A. Lo S.K.M.S. Tafur A.J. Jaslowski A.J. Qadir M.U. Gunturi A. Nazeef M. Raybon K. Kaplan R.I. Andreescu A.C. Sotirescu D. Keech J.C. Malcolm A.S. Andreca F.D. Shah V.I. Leavitt A.D. Marchello B.T. Flora D. Weckstein D. Bangalore N.S. Belmonte J. Montero A. Shah S.P. Constantine M. Faggen M. Briccetti F. Lathan C. D’Agostino R.L. Fenninger R. Delate T. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent vte in patients with cancer. JAMA 2023 329 22 1924 1933 10.1001/jama.2023.7843 37266947
    [Google Scholar]
  22. Riaz I.B. Fuentes H. Deng Y. Naqvi S.A.A. Yao X. Sangaralingham L.R. Houghton D.E. Padrnos L.J. Shamoun F.E. Wysokinski W.E. McBane R.D. II Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis. JAMA Netw. Open 2023 6 7 e2325283 e2325283 10.1001/jamanetworkopen.2023.25283 37486628
    [Google Scholar]
  23. Frere C. Farge D. Schrag D. Prata P.H. Connors J.M. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J. Hematol. Oncol. 2022 15 1 69 10.1186/s13045‑022‑01289‑1 35598026
    [Google Scholar]
  24. Holmes C.E. Ades S. Gilchrist S. Douce D. Libby K. Rogala B. Parenteau E. Cushman M. Holm A.K. Successful model for guideline implementation to prevent cancer-associated thrombosis: Venous thromboembolism prevention in the ambulatory cancer clinic. JCO Oncol. Pract. 2020 16 9 e868 e874 10.1200/JOP.19.00697 32267798
    [Google Scholar]
  25. Pabinger I. van Es N. Heinze G. Posch F. Riedl J. Reitter E.M. Di Nisio M. Cesarman-Maus G. Kraaijpoel N. Zielinski C.C. Büller H.R. Ay C. A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts. Lancet Haematol. 2018 5 7 e289 e298 10.1016/S2352‑3026(18)30063‑2 29885940
    [Google Scholar]
  26. Poénou G. Tolédano E. Helfer H. Plaisance L. Happe F. Versini E. Diab N. Djennaoui S. Mahé I. In search of the appropriate anticoagulant-associated bleeding risk assessment model for cancer-associated thrombosis patients. Cancers (Basel) 2022 14 8 1937 10.3390/cancers14081937 35454844
    [Google Scholar]
  27. Di W. Xu H. Xue T. Ling C. Advances in the prediction and risk assessment of lung cancer-associated venous thromboembolism. Cancer Manag. Res. 2021 13 8317 8327 10.2147/CMAR.S328918 34764694
    [Google Scholar]
  28. Streiff M.B. Holmstrom B. Angelini D. Ashrani A. Elshoury A. Fanikos J. Fertrin K.Y. Fogerty A.E. Gao S. Goldhaber S.Z. Gundabolu K. Ibrahim I. Kraut E. Leavitt A.D. Lee A. Lee J.T. Lim M. Mann J. Martin K. McMahon B. Moriarty J. Morton C. Ortel T.L. Paschal R. Schaefer J. Shattil S. Siddiqi T. Sudheendra D. Williams E. Hollinger L. Nguyen M.Q. Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2021 19 10 1181 1201 34666313
    [Google Scholar]
  29. Elalamy I. Cohen-Solal A. Hanon O. Mirabel M. Mismetti P. Spano J.P. Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice. Curr. Res. Transl. Med. 2023 71 3 103405 10.1016/j.retram.2023.103405 37478777
    [Google Scholar]
  30. Li C. He Q. Wang Z. Fang C. Gong Z. Zhao H. Ling B. Risk assessment of venous thromboembolism in head and neck cancer patients and its establishment of a prediction model. Head Neck 2023 45 10 2515 2524 10.1002/hed.27475 37548087
    [Google Scholar]
  31. McMullen J. Schaefer J. Barnes G.D. Current management of cancer-associated thromboembolism in the prophylactic and acute setting. Curr. Treat. Options Cardiovasc. Med. 2023 25 9 359 377 10.1007/s11936‑023‑00998‑1
    [Google Scholar]
  32. El-Sayed H.A. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models. J. Cancer Res. Clin. Oncol. 2023 149 20 17771 17780
    [Google Scholar]
  33. Chelf J.H. Cancer-related patient education: An overview of the last decade of evaluation and research. Oncol Nurs Forum 2001 28 7 1139 47
    [Google Scholar]
/content/journals/cctr/10.2174/0115733947322285241004075557
Loading
Direct Oral Anticoagulants and Cancer-related Venous Thromboembolism: Insights from an Updated Meta-Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0115733947322285241004075557
/content/journals/cctr/10.2174/0115733947322285241004075557
/content/journals/cctr/10.2174/0115733947322285241004075557
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: thromboprophylaxis ; meta-analysis ; cancer-associated venous thromboembolism ; Direct oral anticoagulants

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test